Holen Sie sich die Stockscreener-App
56.00
1.06%
0.59
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Zacks Investment Research
Blair William & Co. IL Sells 46,183 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Cetera Investment Advisers Grows Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Westwood Holdings Group Inc. Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
3 Monster Stocks in the Making to Buy Right Now - AOL.com
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Barclays Forecasts Strong Price Appreciation for CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at HC Wainwright - MarketBeat
Cantor Fitzgerald Has Weak Estimate for CRSP FY2025 Earnings - MarketBeat
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - MSN
Leerink Partnrs Brokers Reduce Earnings Estimates for CRSP - MarketBeat
CRISPR Therapeutics AG Insider Buying: Douglas Treco Acquires 20,000 Shares - AInvest
CRISPR Therapeutics (NASDAQ:CRSP) Given "Buy" Rating at Chardan Capital - MarketBeat
Crispr Therapeutics Faces Stock Dip Amid Promising Developments - TipRanks
Crispr Therapeutics AG (CRSP) Gets a Buy from Truist Financial - The Globe and Mail
Royal Bank Of Canada Increases CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $42.00 - MarketBeat
Director Makes Bold Move with Major Stock Purchase in Crispr Therapeutics AG! - TipRanks
IQ EQ FUND MANAGEMENT IRELAND Ltd Has $2.22 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - MSN
Crispr Therapeutics price target raised to $12 from $10 at Barclays - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Posts Quarterly Earnings Results - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap DownHere's Why - MarketBeat
CRSP Stock Analysis: What’s Going on with Crispr Therapeutics AG? - Markets.com
Crispr Therapeutics AG: Strong Sales Growth and Global Expansion Justify Buy Rating - TipRanks
Brookline Capital Management Estimates CRSP Q3 Earnings - MarketBeat
Research Analysts Set Expectations for CRSP FY2027 Earnings - MarketBeat
CRISPR Therapeutics stock price target raised to $80 by H.C. Wainwright - Investing.com Nigeria
Banque Cantonale Vaudoise Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Privium Fund Management B.V. Acquires 25,100 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Earnings: Casgevy Launch Gains Momentum; Early-Stage Pipeline Progresses; Shares Undervalued - Morningstar
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption - MSN
CRISPR Therapeutics Shares Drop 6.71% on Q2 Losses and $96M Charge as $250M Volume Ranks 475th - AInvest
Up 50% in 3 Months, Is This Stock Still a Buy? - The Motley Fool
Crispr Therapeutics AG: Strong Financial Foundation and Promising Pipeline Amidst Strategic Growth - TipRanks
CRISPR Therapeutics Plunges 9.63% Ahead of Q2 Earnings - AInvest
Crispr Therapeutics AG: Promising Growth and Expanding Pipeline Justify Buy Rating - TipRanks
Bayforest Capital Ltd Purchases Shares of 12,424 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG reports results for the quarter ended June 30Earnings Summary - TradingView
Crispr Therapeutics shares tumble after significant earnings miss By Investing.com - Investing.com Nigeria
Crispr Therapeutics shares tumble after significant earnings miss - Investing.com
Crispr Therapeutics earnings missed by $1.00, revenue fell short of estimates - Investing.com
CRISPR Therapeutics AG SEC 10-Q Report - TradingView
CRISPR Therapeutics Q2 revenue misses estimates, net loss widens - MarketScreener
0.15%
2.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):